Dibasic Monobasic (Potassium Phosphates) shortage status
Shortage anticipated
Source: Health Canada shortage reports · Updated Sep 14, 2026
A shortage of Dibasic Monobasic is anticipated but not yet confirmed. 1 product(s) have anticipated-shortage reports on file with Health Canada.
Products affected
0 / 2
Reports on file
11
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Anticipated
POTASSIUM PHOSPHATES INJECTION, USP
224MG
236MG · SOLUTION · FRESENIUS KABI CANADA LTD
DIN 02139545 · Disruption of the manufacture of the drug.
Resolved
POTASSIUM PHOSPHATES INJECTION, USP
236MG
224MG · SOLUTION · FRESENIUS KABI CANADA LTD
DIN 02139545 · ended Dec 2, 2024 · Disruption of the manufacture of the drug.
Resolved
POTASSIUM PHOSPHATES INJECTION, USP
236MG
224MG · SOLUTION · FRESENIUS KABI CANADA LTD
DIN 02139545 · ended Dec 2, 2024 · Disruption of the manufacture of the drug.
Resolved
POTASSIUM PHOSPHATES
236MG
224MG · LIQUID · SANDOZ CANADA INCORPORATED
DIN 00804789 · ended May 9, 2023 · Requirements related to complying with good manufacturing practices.
Resolved
POTASSIUM PHOSPHATES INJECTION, USP
236MG
224MG · SOLUTION · FRESENIUS KABI CANADA LTD
DIN 02139545 · ended Apr 12, 2023 · Disruption of the manufacture of the drug.
Resolved
POTASSIUM PHOSPHATES INJECTION, USP
236MG
224MG · SOLUTION · FRESENIUS KABI CANADA LTD
DIN 02139545 · ended Nov 1, 2022
Resolved
POTASSIUM PHOSPHATES INJECTION, USP
236MG
224MG · SOLUTION · FRESENIUS KABI CANADA LTD
DIN 02139545 · ended Apr 30, 2022 · On 100% allocation
Resolved
POTASSIUM PHOSPHATES INJECTION, USP
236MG
224MG · SOLUTION · FRESENIUS KABI CANADA LTD
DIN 02139545 · ended Oct 21, 2021 · Disruption of the manufacture of the drug.
Resolved
POTASSIUM PHOSPHATES INJECTION, USP
224MG
236MG · SOLUTION · FRESENIUS KABI CANADA LTD
DIN 02139545 · ended Jan 22, 2021 · Disruption of the manufacture of the drug.
Resolved
POTASSIUM PHOSPHATES INJECTION, USP
224MG
236MG · SOLUTION · FRESENIUS KABI CANADA LTD
DIN 02139545 · ended Jun 22, 2020 · Disruption of the manufacture of the drug.
Resolved
POTASSIUM PHOSPHATES INJECTION, USP
236MG
224MG · SOLUTION · FRESENIUS KABI CANADA LTD
DIN 02139545 · ended May 26, 2017 · Delay in shipping of the drug.
What's happening
A manufacturer has told Health Canada it expects supply of Dibasic Monobasic to fall short of demand. Anticipated shortages sometimes resolve without patients noticing; this page updates as soon as the status changes.
Dibasic Monobasic is classified under “I.V. SOLUTION ADDITIVES” (ATC B05XA).
Recent changes
Sep 14, 2026
New report filed
Common questions
When will Dibasic Monobasic be back in stock in Canada?
Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.
Why is Dibasic Monobasic in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.